COVID-19: Glycopyrronium (Seebri Breezhaler) Powder
Glycopyrronium (Seebri Breezhaler) can be used treat chronic obstructive pulmonary disease, also called COPD.
Page updated: 18 May 2020
Prescription endorsement requirement removed
We have amended the criteria for funded glycopyrronium (Seebri Breezhaler) Powder for inhalation 50 mcg per dose in Section B of the Pharmaceutical Schedule.
We have remove the requirement for COPD diagnosis by spirometry. This comes into effect on 1 June 2020.
We're making these changes to support the health system while New Zealand is responding to COVID-19.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email firstname.lastname@example.org
Last updated: 19 May 2020